Literature DB >> 2253653

Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects.

J B Lecaillon1, J P Dubois, H Coppens, T Darragon, W Theobald, G Reumond, H Beck.   

Abstract

The pharmacokinetics of oxiracetam have been studied in eighteen elderly patients and in six healthy non-geriatric adults. A 800 mg single oral dose was administered in the morning of the first day and repeatedly, every 12 h, from day 2 evening to day 10 morning, to the elderly patients. The healthy non-geriatric adults were given a 800 mg single oral dose of oxiracetam. In healthy non-geriatric subjects after a single oral administration of 800 mg, the normalized plasma levels of oxiracetam for 1 mg/kg dose were similar to those already recorded after a 2000 mg single dose of oxiracetam. Therefore, there was no tendency towards non-linear pharmacokinetics of oxiracetam between 800 and 2000 mg single doses in healthy subjects. After the single oral dose, the mean area under the plasma concentration-time curve of oxiracetam in elderly patients was increased by a factor of two as compared to that observed in non-geriatric healthy subjects whereas the maximum concentration (Cmax) was almost not modified and slightly delayed. This can be explained by a slower absorption and elimination in the elderly patients. The highest oxiracetam levels were predominantly recorded in the oldest patients. The slower elimination (mean T1/2 = 12.3 h in elderly and 7.7 h in healthy subjects) could be attributed to a physiological decrease of the renal function. The volume of distribution was not significantly modified in the elderly patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253653     DOI: 10.1007/bf03190208

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  6 in total

1.  Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.

Authors:  C Villardita; J Parini; S Grioli; M Quattropani; C Lomeo; U Scapagnini
Journal:  J Neural Transm Suppl       Date:  1987

2.  An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants.

Authors:  A Gerardin; D Wantiez; A Jaouen
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

3.  Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.

Authors:  E Perucca; A Albrici; G Gatti; R Spalluto; M Visconti; A Crema
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

4.  Nomogram for estimating creatinine clearance.

Authors:  T D Bjornsson; D M Cocchetto; F X McGowan; C P Verghese; F Sedor
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

5.  Determination of oxiracetam in plasma and urine by column-switching high-performance liquid chromatography.

Authors:  J B Lecaillon; C Souppart; F Le Duigou; J P Dubois
Journal:  J Chromatogr       Date:  1989-12-29

6.  Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly.

Authors:  E Perucca; J Parini; A Albrici; M Visconti; E Ferrero
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

  6 in total
  2 in total

1.  Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose.

Authors:  J B Lecaillon; J P Dubois; H Coppens; T Darragon; G Reumond; N Pozet; J Traeger; G Lambrey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

2.  Absorption and disposition of 14C-labelled oxiracetam in rat, dog and man.

Authors:  H P Gschwind; H Schütz; N Wigger; P Bentley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.